The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

An expert writes about his experience as a sarcoma medical oncologist and how the field may progress with several therapies in the pipeline. As a sarcoma medical oncologist, the No. 1 question I am ...

Objective response rate was 35% (3 CR, 3 PR), with most patients demonstrating primary progression despite meeting ...

In part 3 of an interview, MD Anderson’s Ravin Ratan, MD, MEd, discusses neoadjuvant immune checkpoint blockade for 2 specific types of soft tissue sarcomas. Liposarcomas originate in fat cells and ...

Patients with soft-tissue sarcoma treated with neoadjuvant, or pre-surgical, immunotherapy had very little residual tumor at the time of surgery and promising long-term survival, according to Phase II ...

Success rates for drug development in solid tumors remain the lowest of the many therapeutics areas in medicine. Recent advances in drug discovery and development have transformed available therapies ...

For the last three decades, breakthroughs have been sparse for soft tissue sarcomas, which are rare cancers that affect muscles, fat and other connective tissues. A global team of researchers have ...